Shares of Coherus (NASDAQ: CHRS) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to ...

Coherus launched YUSIMRY™, a Humira biosimilar, with a citrate-free and sting-free formulation delivered via a state-of-the-art autoinjector July 3, 2023. YUSIMRY™ is now available for sale nationwide ...

REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that effective December 20, 2023, the compensation committee of the Company’s board of ...

Date and Time: Saturday, June 3, 2023, Session: 4:30-5:30 p.m., Presentation: 4:54 p.m. Central Daylight Time The FDA has granted Breakthrough Therapy designations and priority review for the ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

(RTTNews) - Coherus BioSciences Inc. (CHRS) said that McDavid Stilwell, Chief Financial Officer, has resigned from the company to pursue other opportunities. Stilwell's last day of employment with ...

(Reuters) -Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ...

Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release. Analysts are ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Illustration photo shows various medicine pills in their original packaging (Reuters) -Coherus BioSciences said on ...

Coherus BioSciences Q4 2023 Adj EPS $(0.62) M ...

Coherus BioSciences stock initially jumped after the announcement of a deal to sell Cimerli to Sandoz. However, shares are now sinking with investors reminded of the financial challenges that Coherus ...